EMAIL info@prfbd.org
Call Now +880 255 035 439

About US
Projahnmo Research Foundation (PRF)

Projahnmo Research Foundation (PRF), a Bangladeshi NGO, is dedicated to the improvement of health and survival of mothers, newborns, children and their families by conducting high priority translational research. The scope of our research encompasses formative research to design contextually appropriate interventions, testing them to provide evidence for cost-effective, scalable interventions, provide policy support, and conduct implementation research to support the Bangladesh Ministry of Health and Family Welfare (MOH&FW) to scale up evidence-based interventions.

In partnership with the Johns Hopkins University in the USA, the Projahnmo Research Foundation has maintained a state-of-the-art rural research site in Zakiganj sub-district of Sylhet district and developed extensive community- and facility-based research infrastructures, including in an urban research site in Sylhet city corporation area of Sylhet district of Bangladesh. Projahnmo Research Foundation has conducted several high-quality and high-impact clinical and epidemiological studies, the results of which were extensively published in top-ranking international journals and influenced global and national health policies.

Vision

Build a healthier generation

Mission

To promote the health and well-being of families across the life course, with a special focus on mothers, newborns, and children.

Goal

To contribute to building a healthier generation by generating robust evidence and translating it into policies and programs, through strategic partnerships with national and international institutions.

Values

Integrity, technical excellence, collaboration, and compliance

Ongoing Projects

Projahnmo ongoing MNCH and Nutrition Studies by target population and type of study


Target Population Type of Study
Discovery Development * Delivery/ Implementation Research
Maternal • AMANHI/ MOMI**: Developing biological insights and biomarkers of pre-eclampsia • Global Maternal and Newborn Platform • The E-Patient Quality Improvement & Standardization to Improve Clinical Care (EQIS)
• ACS IR
Perinatal/Newborn • AMANHI/MOMI: Developing biological insights and biomarkers of stillbirth, preterm birth, small for gestational age • Steroids in late preterm labor, an RCT
• PSBI treatment trials
• Global Maternal and Newborn Platform
• Probiotic trial (PROPS trial)		 • Scale-up of steroids in early preterm labor
• Scale-up of IKMC
• The E-Patient Quality Improvement & Standardization to Improve Clinical Care (EQIS)
Infant and Child Health • AMANHI/MOMI: Developing biological insights and biomarkers of impaired child growth and neurodevelopment • Nutritional management of growth faltering - RCT.
• Development and validation of tools for measuring child development
• Improving childhood pneumonia diagnosis using digital auscultation
• Bangladesh Lung Auscultation Artificial Intelligence for Antibiotic Stewardship (BLAAST)
• Efficacy of antenatal corticosteroids on the lung function of premature children in Bangladesh
• Antenatal dexamethasone for preterm birth and long-term health outcomes in children.		 • The E-Patient Quality Improvement & Standardization to Improve Clinical Care (EQIS)
Adult/Older population • Climate Change impact on Respiratory Health in Bangladesh
• RSV vaccine trial		 • Leveraging community-to-facility service provision to implement the World Health Organization HEARTS-D guidelines in Bangladesh for improving diabetes control and prevention
Vaccine Trial Moderna Adult RSV Vaccine Trial.
A Phase III, randomized, double-blind, placebo controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 years of age, for prevention of RSV associated LRTI in their infants up to 6 months of age (GSK).
A non-randomized, open label, multi-country, cohort study to describe the safety of study participants who received RSVPreF3 maternal vaccination (any dose) or controls from previous RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010(GSK).
A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in their Infants (Novavax).

*Development of tools or testing of interventions.

** MOMI is a consortium of six biorepositories in South Asia and sub-Saharan Africa and several universities, including Stanford, USCF, and Cincinnati Children, funded by BMGF. The overarching goal of MOMI is to improve the health of mothers, babies, and children by developing biological insights and biomarkers.

Ongoing Projects

MILESTONE

PRF Founder and Senior Adviser Professor Abdullah Baqui received The Carl E. Taylor Lifetime Achievement Award from the American Public Health Association. This award honors a visionary public health leader for making a global impact.
Abdullah Baqui also received the following other awards.

- Dory Storms recognition award by CORE group for outstanding research on newborn and child health. Since 2001, CORE Group has presented the annual Dory Storms Child Survival Recognition Award to a person or persons who demonstrate courage, leadership, and commitment to helping non-governmental organizations have an impact on and effectively implement programs that end child deaths.

- Bangladesh Medical Association of North America recognition award for exceptional efforts resulting in a more effective maternal and newborn health program that has improved the health of the poor, including mothers, children, and infants in underserved communities throughout the world.

- The Lancet’s paper of the year 2008: This award recognized the work of Abdullah Baqui and his colleagues, who developed a contextually appropriate community-based intervention and evaluated it using a cluster randomized trial and demonstrated a one-third decline in neonatal mortality in the Sylhet district of Bangladesh. According to the Lancet, such efforts have helped to reduce annual worldwide mortality in under-5-year-olds from nearly 13 million in 1990 to less than 10 million in 2007.

COMPLETED PROJECTS


SELECTED COMPLETED PROJECTS

SUCCESS STORIES

We have conducted several high quality and high impact clinical and epidemiological studies, the results of which were extensively published in top ranking international journals and influenced the global and national health policies.
Read More

Contact Us

Direction

ADDRESS

Floor 7, House: 97A, Road: 25, Block # A, Banani, Dhaka-1213, Bangladesh

Phone

+880 255 035 439

Email

info@prfbd.org
Copyright 2026 © Developed By Projahnmo Research Foundation